Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.
Metastatic Malignant Melanoma
DRUG: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel
Overall Response Rate as assessed by RECIST 1.1 and immune-related Response Criteria, 56 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, 56 months|Overall Survival, 56 months|Progression Free Survival, 56 months|Melanoma-associated serological markers by multiplexed array will be generated, 56 months
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.